SUBSCRIBE
SUBSCRIBE
News   Drug Development

AstraZeneca PLC’s Brilinta Outshines Rival Sanofi-Aventis (France)'s Plavix in Studies

August 30, 2010 | 
1 min read
STOCKHOLM (Reuters) - Gene testing is shaping up to be a marketing battleground for new blood thinners like AstraZeneca's Brilinta, underscoring the power and limitations of genetics as a tool to predict medical outcomes.
Clinical research Phase 3 Europe
AstraZeneca Sanofi
MORE ON THIS TOPIC
Digital overload and its impact on the human brain, showcasing fragmented thoughts, information overload. Abstract design art collage. Social media digital addiction, mental health, stress, anxiety
Neuropsychiatric disorders
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears
June 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Businessmen look at the city from the outskirts.
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
June 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Plan to buying new house or renovation, mortgage loan or housing expense, property maintenance or real estate insurance concept, smart businessman put jigsaw to complete or finishing house puzzle.
FDA
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year
June 25, 2026
 · 
3 min read
 · 
Jef Akst
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker